L26/P-185 Impact of In-Vitro Recombinant Anti-Müllerian Hormone Treatment on Pre-implantation Human Blastocyst RNA Expression
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von C. Arkfeld und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does treatment with recombinant human anti-Müllerian hormone (AMH) impact the RNA expression of human blastocysts? Summary answer Exogenous AMH exposure decreases RNA expression of human chorionic gonadotropin (hCG) subunits and CYP19A1 in XX pre-implantation human blastocysts compared to controls without AMH pretreatment. What is known already AMH, a TGF-β superfamily ligand, is critical in sexual differentiation. In adult females, elevated serum AMH is a marker of polycystic ovary syndrome (PCOS), which is associated with infertility and adverse pregnancy outcomes. Follicular-fluid AMH and granulosa-cell AMH receptor (AMHR2) expression has been linked with oocyte quality, blastocyst development, and IVF outcomes. CYP19A1, a cytochrome P450 monooxygenase, catalyzes androgen-to-estrogen conversion which is essential for folliculogenesis and endometrial function. Human chorionic gonadotropin (hCG), produced by the preimplantation blastocyst binds endometrial receptors modulating receptivity before it is detected in maternal serum. The relationship between AMH, CYP19A1, and hCG has not been described. Study design, size, duration Single-center study using human blastocysts cryopreserved on day-5 donated for research. After warming, blastocysts were cultured for 24-hours in control medium (PBS vehicle) or medium with recombinant human AMH (1.0µg/mL). Blastocyst sex was determined by a digital sexing algorithm based on sex-chromosome Z-scores; digital karyotyping employed Z-score normalization across autosomal chromosomes and aneuploid blastocysts were excluded. 45 preimplantation blastocysts were analyzed: 23 controls (14 XX, 9 XY) and 22 AMH-treated (9 XX, 13 XY). Participants/materials, setting, methods All blastocysts were individually processed with a modified single blastocyst workflow of SmartSeqV4 library preparation. Indexed libraries were sequenced on a full-flow cell of a Novaseq sequencer with 6 million read pairs per sample. The Broad Institute Smart-seq2 Single Sample Pipeline (RRID:SCR_021228) processed RNA-seq data. Differentially expressed genes (DEGs) between AMH-treated and control blastocysts were identified with edgeR package (v3.42.0). Values are presented as log fold change, with false discovery rate (FDR)<0.05 considered statistically significant. Main results and the role of chance Multiple suppressed genes in AMH-treated XX blastocysts versus XX controls were identified. Specifically, AMH treatment downregulated the chorionic gonadotropin subunit beta 8 (CGB8) gene (-7.90, FDR = 0.00052), the chorionic gonadotropin subunit beta 5 (CGB5) gene (-7.01, FDR= 1.38E-05), and chorionic gonadotropin subunit alpha (CGA) gene (-8.79, FDR=0.00073) expressions. Additionally, the CYP19A1 gene was downregulated with AMH treatment (-3.31, FDR=0.034). Conversely, there were no differences noted between treatment groups for the XY blastocysts. FeaturePlot visualization of normalized expression matrices for AMHR2, CGA, CGB5, and CGB8 confirmed lineage-specific expression patterns observed in our bulk single-embryo dataset and matched public single-cell RNA-seq data. Notably, AMHR2 and CYP19A1 were co-expressed within the same cell lines; their overlap was predominantly localized to trophectoderm-specific cells. Limitations, reasons for caution Limitations include the small sample size. Larger studies are needed to validate whether exogenous AMH consistently alters pre-implantation transcriptomes. Future work should integrate exogenous AMH treatment and clinical PCOS diagnosis, with endogenous serum AMH levels, to confirm AMH specific treatment effects on human pre-implantation blastocysts. Wider implications of the findings This is the first study demonstrating in-vitro AMH exposure alters RNA expression in human pre-implantation blastocysts. Results implicate AMH in early androgen pathway regulation and a sex-specific mechanism by which AMH may contribute to PCOS-related outcomes. Longitudinal, multi-generational studies are needed to assess persistence and transgenerational inheritance in XX offspring. Trial registration number No
Zitieren
APA
Arkfeld, C., Mermin-Bunnell, A., Vagios, S., Minis, E., Fitz, V., Souter, I., Bormann, C., & Pepin, D. (2026). L26/P-185 Impact of In-Vitro Recombinant Anti-Müllerian Hormone Treatment on Pre-implantation Human Blastocyst RNA Expression. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.521
Vancouver
Arkfeld C, Mermin-Bunnell A, Vagios S, Minis E, Fitz V, Souter I, et al. L26/P-185 Impact of In-Vitro Recombinant Anti-Müllerian Hormone Treatment on Pre-implantation Human Blastocyst RNA Expression. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.521
BibTeX
@article{Arkfeld2026,
author = {Arkfeld, C. and Mermin-Bunnell, A. and Vagios, S. and Minis, E. and Fitz, V. and Souter, I. and Bormann, C. and Pepin, D.},
title = {L26/P-185 Impact of In-Vitro Recombinant Anti-Müllerian Hormone Treatment on Pre-implantation Human Blastocyst RNA Expression},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.521}
}
EUVIMED